Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2018

View Archived Issues

Autoantibodies contribute to memory dysfunction

Early diagnosis of gestational diabetes

Release of safety and efficacy data of pinometostat for the treatment of acute advanced leukemia

Preclinical identification of a potential druggable target for chronic kidney disease

Dissemination of data from four phase I studies GSK-2838232, a second-generation drug for HIV

Sunitinib noninferior to nephrectomy in patients with metastatic renal-cell carcinoma

Potential new anti-obesity target identified

GT Biopharma initiates OXS-1550 combination study with a multi billion dollar oncology drug

Biogen describes new mitogen-activated protein kinase kinase kinase 5 inhibitors

TGF-beta decoy receptors patented by Tessa Therapeutics

Inovelon receives marketing authorisation extension in Europe

Updated data presented from long-term extension phase Ib study of aducanumab

First patient dosed in phase III study of ZL-2306 in SCLC

Positive topline data presented from phase Ib study of TAR-302 in idiopathic overactive bladder

AZD-5718: an oral FLAP inhibitor for the treatment of CAD

Development of a new PAM for the treatment of Parkinson's disease

Gradalis initiates phase III study of Vigil in Ewing's sarcoma

Clinical trials completed for Celltrion's Remsima SC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...